NMO
MCID: NRM001
MIFTS: 60

Neuromyelitis Optica (NMO) malady

Categories: Rare diseases, Neuronal diseases, Eye diseases

Aliases & Classifications for Neuromyelitis Optica

Aliases & Descriptions for Neuromyelitis Optica:

Name: Neuromyelitis Optica 38 12 50 25 51 56 52 42 14 69
Devic Disease 50 25 56
Devic's Syndrome 12 51
Devic's Disease 12 25
Devic Syndrome 50 25
Opticospinal Multiple Sclerosis 69
Devic's Neuromyelitis Optica 50
Devic Neuromyelitis Optica 25
Optic-Spinal Ms 25
Opticospinal Ms 25
Nmo 50

Characteristics:

Orphanet epidemiological data:

56
neuromyelitis optica
Inheritance: Multigenic/multifactorial; Prevalence: 1-9/100000 (Europe); Age of onset: All ages; Age of death: any age;

Classifications:



External Ids:

Disease Ontology 12 DOID:8869
ICD10 33 G36.0
ICD9CM 35 341.0
MeSH 42 D009471
NCIt 47 C84934
SNOMED-CT 64 25044007
Orphanet 56 ORPHA71211
MESH via Orphanet 43 D009471
UMLS via Orphanet 70 C0027873
ICD10 via Orphanet 34 G36.0
UMLS 69 C0027873

Summaries for Neuromyelitis Optica

NINDS : 51 Neuromyelitis optica (NMO) is an autoimmune disease of the central nervous system (CNS) that predominantly affects the optic nerves and spinal cord. It is sometimes also referred to as NMO spectrum disorder.In NMO, the body's immune system mistakenly attacks healthy cells and proteins in the body, must often those in the spinal cord and eyes. Individuals with NMO develop optic neuritis, which caused pain in the eye and vision loss. Individuals also develop transverse myelitis, which causes weakness or paralysis of arms and legs,and numbness, along with loss of bladder and bowel control Magnetic resonance imaging of the spine often shows an abnormality that extends over  long segments of the spinal cord. Individuals may also develop episodes of severe nausea and vomiting, with hiccups from involvement of a part of the brain that ocntrols vomiting The disease is caused by abnormal autoantibodies that bind to a protein called aquaporin-4. Binding of the aquaporin-4 antibody activates other components of the immune system, causing inflammation and damage to these cells. This also results in the brain and spinal cord the loss of myelin, the fatty substance that acts as insulation around nerve fibers and helps nerve signals move from cell to cell. 

MalaCards based summary : Neuromyelitis Optica, also known as devic disease, is related to neuromyelitis optica spectrum disorder and transverse myelitis, and has symptoms including seizures, nausea and vomiting and dysautonomia. An important gene associated with Neuromyelitis Optica is AQP4 (Aquaporin 4), and among its related pathways/superpathways are Allograft rejection and Th17 cell differentiation. The drugs Mitoxantrone and Mycophenolic acid have been mentioned in the context of this disorder. Affiliated tissues include Umbilical Cord, spinal cord and brain, and related phenotypes are behavior/neurological and growth/size/body region

Disease Ontology : 12 A central nervous system disease characterized by inflammation of the optic nerve (optic neuritis) and inflammation of the spinal cord (myelitis).

Genetics Home Reference : 25 Neuromyelitis optica is an autoimmune disorder that affects the nerves of the eyes and the central nervous system, which includes the brain and spinal cord. Autoimmune disorders occur when the immune system malfunctions and attacks the body's own tissues and organs. In neuromyelitis optica, the autoimmune attack causes inflammation of the nerves, and the resulting damage leads to the signs and symptoms of the condition.

NIH Rare Diseases : 50 neuromyelitis optica, is an autoimmune condition that affects the spinal cord and optic nerves (the nerves that carry information regarding sight from the eye). in neuromyelitis optica, the body's immune system attacks and destroys myelin, a fatty substance that surrounds nerves and helps nerve signals move from cell to cell. signs and symptoms worsen with time and include optic neuritis; transverse myelitis; pain in spine and limbs; and bladder and bowel dysfunction. the exact cause of neuromyelitis optica is unknown. most affected people do not have other family members with the condition. currently there is no cure for neuromyelitis optica, but there are therapies to treat an attack while it is happening, to reduce symptoms, and to prevent relapses. last updated: 12/5/2014

Wikipedia : 71 Neuromyelitis optica (NMO), also known as Devic\'s disease or Devic\'s syndrome, is a heterogeneous... more...

Related Diseases for Neuromyelitis Optica

Diseases in the Neuromyelitis Optica family:

Neuromyelitis Optica Spectrum Disorder

Diseases related to Neuromyelitis Optica via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 156)
id Related Disease Score Top Affiliating Genes
1 neuromyelitis optica spectrum disorder 12.3
2 transverse myelitis 11.5
3 myelitis 10.6
4 optic neuritis 10.6
5 neuritis 10.6
6 retinitis 10.3
7 children's interstitial lung disease 10.3 GFAP MBP
8 crest syndrome 10.3 AQP4 MBP
9 neonatal hypoxic and ischemic brain injury 10.2 AQP4 IL6
10 central neurocytoma 10.2 AQP4 GFAP
11 alopecia-intellectual disability syndrome 10.2 MBP MOG
12 swine influenza 10.2 HLA-DRB1 IL6
13 angiomatosis, diffuse corticomeningeal, of divry and van bogaert 10.2 HLA-DRB1 IL6
14 cerebritis 10.2
15 splenic marginal zone lymphoma 10.2 AQP4 GFAP IL6
16 caplan's syndrome 10.2 HLA-DPB1 HLA-DRB1
17 penis agenesis 10.2 HLA-DRB1 MOG
18 schwannoma of twelfth cranial nerve 10.2 AQP4 MBP MOG
19 breast reconstruction 10.2 GFAP IL6 MBP
20 bilateral parasagittal parieto-occipital polymicrogyria 10.2 HLA-DPB1 HLA-DRB1
21 status epilepticus 10.2 AQP4 MBP MOG
22 distal trisomy 14q 10.2 HLA-DPB1 HLA-DRB1
23 nerve fibre bundle defect 10.2 AQP4 MBP MOG
24 myasthenia gravis 10.1
25 cervicitis 10.1
26 acute disseminated encephalomyelitis 10.1
27 systemic lupus erythematosus 10.1
28 lupus erythematosus 10.1
29 thalassemia 10.1 AQP4 GFAP SLC1A2
30 ehlers-danlos syndrome, kyphoscoliotic form 10.1 AQP1 AQP4
31 human immunodeficiency virus infectious disease 10.1 HLA-DRB1 IL6
32 ovarian cancer 10.1 GFAP SLC1A2
33 superior vena cava syndrome 10.1 AQP1 AQP4 GFAP
34 intracranial arteriosclerosis 10.1 IL6 MBP SLC1A2
35 leydig cell hypoplasia 10.1 IL6 MBP SLC1A2
36 childhood brainstem astrocytoma 10.1 AQP1 AQP4 MBP
37 ovarian disease 10.1 AQP1 AQP4 MBP
38 urethral gland abscess 10.1 AQP1 AQP4 HLA-DRB1
39 encephalitis 10.1
40 demyelinating disease 10.1
41 neuropathy 10.1
42 urea cycle disorder 10.1 AQP4 GFAP IL6 MBP
43 pulmonary hemosiderosis 10.1 AQP4 HLA-DRB1 MBP MOG
44 pemphigus vulgaris, familial 10.1 HLA-DPB1 HLA-DRB1 IL6
45 parasitic helminthiasis infectious disease 10.1 HLA-DPB1 HLA-DRB1 MOG
46 intracranial hemorrhage in brain cerebrovascular malformations 10.1 HLA-DPB1 HLA-DRB1 IL6
47 tuberculosis 10.1
48 encephalopathy 10.1
49 dystonia 10.1
50 reproductive system disease 10.0 HLA-DRB1 IL17A IL6

Graphical network of the top 20 diseases related to Neuromyelitis Optica:



Diseases related to Neuromyelitis Optica

Symptoms & Phenotypes for Neuromyelitis Optica

Human phenotypes related to Neuromyelitis Optica:

56 32 (show all 18)
id Description HPO Frequency Orphanet Frequency HPO Source Accession
1 seizures 56 32 Occasional (29-5%) HP:0001250
2 nausea and vomiting 56 32 Occasional (29-5%) HP:0002017
3 dysautonomia 56 32 Very frequent (99-80%) HP:0002459
4 increased intracranial pressure 56 32 Occasional (29-5%) HP:0002516
5 cognitive impairment 56 32 Occasional (29-5%) HP:0100543
6 anxiety 56 32 Occasional (29-5%) HP:0000739
7 hyperthyroidism 56 32 Occasional (29-5%) HP:0000836
8 visual loss 56 32 Occasional (29-5%) HP:0000572
9 hyperkalemia 56 32 Occasional (29-5%) HP:0002153
10 tetraparesis 56 32 Frequent (79-30%) HP:0002273
11 sensory impairment 56 32 Very frequent (99-80%) HP:0003474
12 abnormality of the cerebrospinal fluid 56 32 Occasional (29-5%) HP:0002921
13 autoimmune antibody positivity 56 32 Frequent (79-30%) HP:0030057
14 spinal cord lesion 56 32 Frequent (79-30%) HP:0100561
15 hyperproteinemia 56 32 Frequent (79-30%) HP:0002152
16 abnormality of the urinary system physiology 56 32 Frequent (79-30%) HP:0011277
17 abnormal leukocyte count 56 32 Frequent (79-30%) HP:0011893
18 hypochloremia 56 32 Occasional (29-5%) HP:0003113

MGI Mouse Phenotypes related to Neuromyelitis Optica:

44
id Description MGI Source Accession Score Top Affiliating Genes
1 behavior/neurological MP:0005386 9.86 AQP1 AQP4 GFAP HCRT IL6 MBP
2 growth/size/body region MP:0005378 9.81 AQP1 AQP4 GFAP HCRT IL17A IL6
3 nervous system MP:0003631 9.56 AQP1 AQP4 GFAP HCRT IL6 MBP
4 vision/eye MP:0005391 9.1 AQP4 GFAP IL6 MBP MOG AQP1

Drugs & Therapeutics for Neuromyelitis Optica

Drugs for Neuromyelitis Optica (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 80)
id Name Status Phase Clinical Trials Cas Number PubChem Id
1
Mitoxantrone Approved, Investigational Phase 4 65271-80-9 4212
2
Mycophenolic acid Approved Phase 4 24280-93-1 446541
3
Mycophenolate mofetil Approved, Investigational Phase 4 128794-94-5 5281078
4
Prednisone Approved, Vet_approved Phase 4 53-03-2 5865
5 Analgesics Phase 4
6 glucocorticoids Phase 4,Phase 3,Phase 1
7 Topoisomerase Inhibitors Phase 4
8 Hormone Antagonists Phase 4,Phase 3,Phase 1
9 Hormones Phase 4,Phase 3,Phase 1
10 Peripheral Nervous System Agents Phase 4,Phase 3,Phase 1
11 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 4,Phase 3,Phase 1
12 Anti-Inflammatory Agents Phase 4,Phase 3,Phase 1
13 Antineoplastic Agents, Hormonal Phase 4,Phase 3,Phase 1
14 Immunosuppressive Agents Phase 4,Phase 2,Phase 3,Phase 1
15 Anti-Bacterial Agents Phase 4
16 Antibiotics, Antitubercular Phase 4
17
Prednisolone Approved, Vet_approved Phase 3,Phase 1,Phase 2 50-24-8 5755
18
Methylprednisolone Approved, Vet_approved Phase 3,Phase 1,Phase 2 83-43-2 6741
19
Azathioprine Approved Phase 2, Phase 3 446-86-6 2265
20
rituximab Approved Phase 2, Phase 3,Phase 1 174722-31-7 10201696
21 Prednisolone acetate Phase 3,Phase 1,Phase 2
22 Gastrointestinal Agents Phase 3,Phase 1
23 Neuroprotective Agents Phase 3,Phase 1
24 Prednisolone hemisuccinate Phase 3,Phase 1,Phase 2
25 Prednisolone phosphate Phase 3,Phase 1,Phase 2
26 Protective Agents Phase 3,Phase 1
27 Antiemetics Phase 3,Phase 1
28 Methylprednisolone acetate Phase 3,Phase 1,Phase 2
29 Methylprednisolone Hemisuccinate Phase 3,Phase 1,Phase 2
30 Autonomic Agents Phase 3,Phase 1
31 Immunoglobulins Phase 2, Phase 3, Phase 1
32 gamma-Globulins Phase 3,Phase 2
33 Immunoglobulins, Intravenous Phase 3,Phase 2
34 Antimetabolites Phase 2, Phase 3
35 Antimetabolites, Antineoplastic Phase 2, Phase 3
36 Rho(D) Immune Globulin Phase 3,Phase 2
37 Antibodies Phase 2, Phase 3, Phase 1
38 Antirheumatic Agents Phase 2, Phase 3,Phase 1
39 Antibodies, Monoclonal Phase 2, Phase 3,Phase 1
40
Metoclopramide Approved, Investigational Phase 2 364-62-5 4168
41
Hydrocortisone Approved, Vet_approved Phase 2 50-23-7 5754 657311
42
Histamine Approved, Investigational Phase 1, Phase 2 75614-87-8, 51-45-6 774
43
Cetirizine Approved Phase 1, Phase 2 83881-51-0 2678
44
Cyclophosphamide Approved, Investigational Phase 1, Phase 2 50-18-0, 6055-19-2 2907
45
Mesna Approved Phase 1, Phase 2 3375-50-6 598
46
Dexamethasone Approved, Investigational, Vet_approved Phase 1, Phase 2 50-02-2 5743
47
4-Aminopyridine Approved Phase 2 504-24-5 1727
48
Bortezomib Approved, Investigational Phase 2 179324-69-7 387447 93860
49
Chlorpheniramine Phase 2 113-92-8, 132-22-9 2725
50
protease inhibitors Phase 2,Phase 1

Interventional clinical trials:

(show all 42)
id Name Status NCT ID Phase
1 Efficacy and Safety of Mitoxantrone in Patients With Refractory Neuromyelitis Optica and Spectrum Disorders Unknown status NCT02021825 Phase 4
2 A Pilot Study of Mitoxantrone for the Treatment of Recurrent Neuromyelitis Optica (Devic’s Disease) Completed NCT00304291 Phase 4
3 Mycophenolate Mofetil Treatment With Neuromyelitis Optica Spectrum Disorders in Chinese Patients Enrolling by invitation NCT02809079 Phase 4
4 Phase III Randomized, Double-Blind, Sham-Controlled Study of Plasma Exchange for Acute Severe Attacks of Inflammatory Demyelinating Disease Refractory to Intravenous Methylprednisolone Unknown status NCT00004645 Phase 3
5 Comparison of Clinical Effects of Azathioprine and Rituximab NMO-SD Patients Completed NCT03002038 Phase 2, Phase 3
6 A Double-masked, Placebo-controlled Study With Open Label Period to Evaluate MEDI-551 in Neuromyelitis Optica and Neuromyelitis Optica Spectrum Disorders Recruiting NCT02200770 Phase 2, Phase 3
7 A Double Blind Trial To Evaluate The Safety And Efficacy Of Eculizumab In Relapsing NMO Patients (PREVENT Study) Recruiting NCT01892345 Phase 3
8 Efficacy and Safety Study as Monotherapy of SA237 to Treat NMO and NMOSD Recruiting NCT02073279 Phase 3
9 Efficacy and Safety Study as Add-on Therapy of SA237 to Treat NMO and NMOSD Recruiting NCT02028884 Phase 3
10 An Open Label Extension Trial of Eculizumab in Relapsing NMO Patients Enrolling by invitation NCT02003144 Phase 3
11 A Multicentre randomiSed Controlled TRial of IntraVEnous Immunoglobulin Versus Standard Therapy for Transverse Myelitis Terminated NCT02398994 Phase 3
12 Safety and Efficacy of Umbilical Cord Mesenchymal Stem Cell Therapy for Patients With Progressive Multiple Sclerosis and Neuromyelitis Optica Unknown status NCT01364246 Phase 1, Phase 2
13 Autologous Mesenchymal Stem Cells for the Treatment of Neuromyelitis Optica Spectrum Disorders Unknown status NCT02249676 Phase 2
14 An Open Label Study of the Effects of Eculizumab in Neuromyelitis Optica Completed NCT00904826 Phase 1, Phase 2
15 Neuromyelitis Optica (NMO) & Cetirizine Completed NCT02865018 Phase 1, Phase 2
16 Phase II Clinical Trial of NPB-01 in Patients With Anti-aquaporin 4 Antibody Positive Neuromyelitis Optica Spectrum Disorder Not Provided Adequate Effect of Therapy to Steroids Plus Therapy. Completed NCT01845584 Phase 2
17 Hematopoietic Stem Cell Transplant in Devic's Disease Recruiting NCT00787722 Phase 1, Phase 2
18 Autologous Hematopoietic Stem Cell Transplant in Neuromyelitis Optica Active, not recruiting NCT01339455 Phase 1, Phase 2
19 Efficacy and Safety of Bortezomib as add-on Treatment in Relapsing Neuromyelitis Optica Spectrum Disorder Active, not recruiting NCT02893111 Phase 2
20 A Longitudinal Study of ACTEMRA® (Tocilizumab) as Monotherapy in Highly Active NMOSD Active, not recruiting NCT03062579 Phase 1, Phase 2
21 Safety and Efficacy of Sustained Release Dalfampridine in Transverse Myelitis (Re-Launch) Active, not recruiting NCT02166346 Phase 2
22 Pilot Study of alpha1-antitrypsin to Treat Neuromyelitis Optica Relapses Unknown status NCT02087813 Phase 1
23 C1-esterase Inhibitor (Cinryze) for Acute Treatment of Neuromyelitis Optica Exacerbation Completed NCT01759602 Phase 1
24 Safety and Tolerability of Rituximab in Neuromyelitis Optica Completed NCT00501748 Phase 1
25 Efficacy of Bevacizumab (Avastin) in Treatment of Acute NMO Exacerbations Completed NCT01777412 Phase 1
26 Central Pain Study for ABX-1431 Recruiting NCT03138421 Phase 1
27 Ublituximab for Acute Neuromyelitis Optica (NMO) Relapses Active, not recruiting NCT02276963 Phase 1
28 Treatment of Multiple Sclerosis and Neuromyelitis Optica With Regulatory Dendritic Cell: Clinical Trial Phase 1 B Active, not recruiting NCT02283671 Phase 1
29 A Longitudinal Study of Neuromyelitis Optica and Transverse Myelitis Unknown status NCT01623076
30 Evaluation of Neural Loss in Multiple Sclerosis and Neuromyelitis Optica Using High Resolution Oct Unknown status NCT01024985
31 Multimodel Magnetic Resonance Imaging (MRI)of Multiple Sclerosis and Neuromyelitis Optica Spectrum Disorders Recruiting NCT02836327
32 The French Cohort and Biobank of Devic's Neuromyelitis Optica and Related Neurological Disorders (NMOSD) (NOMADMUS) Recruiting NCT02850705
33 The French Multiple Sclerosis Registry Recruiting NCT02889965
34 The Correlation Between AQP-4 Ab and the Visual Function of Patients With Demyelinating ON at Onset Recruiting NCT02886377
35 Optical Coherence Tomography and Optic Neuritis (OCTON) Recruiting NCT02573792
36 Quantitation of McArdle's Sign and Evaluation of Specificity for Multiple Sclerosis Recruiting NCT03122873
37 Analysis of the Distribution of Regulatory B Cells in Blood of Multiple Sclerosis Patients Recruiting NCT02789670
38 Stem Cell Ophthalmology Treatment Study II Recruiting NCT03011541
39 Stem Cell Ophthalmology Treatment Study Recruiting NCT01920867
40 Maintenance Plasma Exchange for Neuromyelitis Optica Active, not recruiting NCT01500681
41 Biobank For MS And Other Demyelinating Diseases Active, not recruiting NCT00445367
42 Pathologic-MRI Findings in Atypical IIDD Active, not recruiting NCT03121105

Search NIH Clinical Center for Neuromyelitis Optica

Cell-based therapeutics:


LifeMap Discovery
Data from LifeMap, the Embryonic Development and Stem Cells Database
Read about Neuromyelitis Optica cell therapies at LifeMap Discovery.

Cochrane evidence based reviews: neuromyelitis optica

Genetic Tests for Neuromyelitis Optica

Anatomical Context for Neuromyelitis Optica

MalaCards organs/tissues related to Neuromyelitis Optica:

39
Spinal Cord, Brain, Eye, T Cells, B Cells, Neutrophil, Hypothalamus
LifeMap Discovery
Data from LifeMap, the Embryonic Development and Stem Cells Database

Cells/anatomical compartments in embryo or adult related to Neuromyelitis Optica:
id Tissue Anatomical CompartmentCell Relevance
1 Umbilical Cord Wharton's Jelly Mesenchymal Stem Cells Potential therapeutic candidate

Publications for Neuromyelitis Optica

Articles related to Neuromyelitis Optica:

(show top 50) (show all 878)
id Title Authors Year
1
Comparison of brain and spinal cord magnetic resonance imaging features in neuromyelitis optica spectrum disorders patients with or without aquaporin-4 antibody. ( 28427704 )
2017
2
Neuromyelitis optica spectrum disorder diagnostic criteria: Sensitivity and specificity are both important. ( 28080211 )
2017
3
Retinal segmented layers with strong aquaporin-4 expression suffered more injuries in neuromyelitis optica spectrum disorders compared with optic neuritis with aquaporin-4 antibody seronegativity detected by optical coherence tomography. ( 28057643 )
2017
4
Efficacy and safety of rituximab in neuromyelitis optica: Review of evidence. ( 28458709 )
2017
5
Role of AQP4 antibody serostatus and its prediction of visual outcome in neuromyelitis optica: a systematic review and meta-analysis. ( 28071581 )
2017
6
Effectiveness and safety of immunosuppressive therapy in neuromyelitis optica spectrum disorder during pregnancy. ( 28477712 )
2017
7
Child Neurology: Neuromyelitis optica spectrum disorders. ( 28069981 )
2017
8
Anti-N-methyl-D-aspartate receptor(NMDAR) antibody encephalitis presents in atypical types and coexists with neuromyelitis optica spectrum disorder or neurosyphilis. ( 28056870 )
2017
9
Neuromyelitis optica presenting as acute bilateral ptosis. ( 27888234 )
2017
10
Letter re: Gray matter MRI differentiates neuromyelitis optica from multiple sclerosis using random forest. ( 28483993 )
2017
11
Neuromyelitis Optica: Deciphering a Complex Immune-Mediated Astrocytopathy. ( 28410278 )
2017
12
Effects of neuromyelitis optica-IgG at the blood-brain barrier in vitro. ( 28018943 )
2017
13
Comparisons of the efficacy and tolerability of mycophenolate mofetil and azathioprine as treatments for neuromyelitis optica and neuromyelitis optica spectrum disorder. ( 27783452 )
2017
14
Treatment of neuromyelitis optica and neuromyelitis optica spectrum disorders with rituximab using a maintenance treatment regimen and close CD19 B cell monitoring. A six-year follow-up. ( 28017256 )
2017
15
Neuromyelitis optica spectrum disorder related tonic spasms responsive to lacosamide. ( 28427706 )
2017
16
Syndrome of inappropriate antidiuretic hormone secretion associated with seronegative neuromyelitis optica spectrum disorder. ( 28393003 )
2017
17
RETINAL VASCULITIS ASSOCIATED WITH NEUROMYELITIS OPTICA. ( 27820753 )
2017
18
LC-MS/MS Analysis of Erythrocyte Thiopurine Nucleotides and Their Association With Genetic Variants in Patients With Neuromyelitis Optica Spectrum Disorders Taking Azathioprine. ( 27941536 )
2017
19
Clinical characteristics of late-onset neuromyelitis optica spectrum disorder: A multicenter retrospective study in Korea. ( 28058965 )
2017
20
Neuromyelitis Optica Spectrum Disorders. ( 28391784 )
2017
21
Screening for onconeural antibodies in neuromyelitis optica spectrum disorders. ( 28068933 )
2017
22
Author response: Gray matter MRI differentiates neuromyelitis optica from multiple sclerosis using random forest. ( 28483994 )
2017
23
Neuromyelitis optica spectrum disease characteristics in Isfahan, Iran: A cross-sectional study. ( 28465700 )
2017
24
Comparative molecular dynamics study of neuromyelitis optica-immunoglobulin G binding to aquaporin-4 extracellular domains. ( 28477975 )
2017
25
Short segment myelitis as a first manifestation of neuromyelitis optica spectrum disorders. ( 28067584 )
2017
26
Deep gray matter atrophy in neuromyelitis optica spectrum disorder and multiple sclerosis. ( 28009104 )
2017
27
Aquaporin-4 positive neuromyelitis optica spectrum disorders secondary to thrombopenic purpura: A case report. ( 28079804 )
2017
28
Foveal thinning in neuromyelitis optica: A sign of retinal astrocytopathy? ( 28439528 )
2017
29
A treatable cause of myelopathy and vision loss mimicking neuromyelitis optica spectrum disorder: late-onset biotinidase deficiency. ( 28281033 )
2017
30
Disruption of the leptomeningeal blood barrier in neuromyelitis optica spectrum disorder. ( 28451627 )
2017
31
Elevated C-X-C motif ligand 13 and B-cell-activating factor levels in neuromyelitis optica during remission. ( 28413701 )
2017
32
Efficacy and safety of tacrolimus treatment for neuromyelitis optica spectrum disorder. ( 28400553 )
2017
33
Pregnancy in neuromyelitis optica spectrum disorder: A multicenter study from South China. ( 28017203 )
2017
34
Paroxysmal tonic spasms as an initial manifestation of neuromyelitis optica. ( 28488634 )
2017
35
Predictors of response to first-line immunosuppressive therapy in neuromyelitis optica spectrum disorders. ( 28080220 )
2017
36
Pruritus may be a common symptom related to neuromyelitis optica spectrum disorders. ( 28427688 )
2017
37
Treatment-resistant neuromyelitis optica spectrum disorders associated with Toxocara canis infection: A case report. ( 28427692 )
2017
38
Abnormal distribution of AQP5 in labial salivary glands is associated with poor saliva secretion in patients with SjAPgren's syndrome including neuromyelitis optica complicated patients. ( 26375433 )
2016
39
Quantitative Susceptibility Mapping Indicates a Disturbed Brain Iron Homeostasis in Neuromyelitis Optica - A Pilot Study. ( 27171423 )
2016
40
Increased occurrence of anti-AQP4 seropositivity and unique HLA Class II associations with neuromyelitis optica (NMO), among Muslim Arabs in Israel. ( 27049564 )
2016
41
Serological prevalence of celiac disease in Brazilian population of multiple sclerosis, neuromyelitis optica and myelitis. ( 27645359 )
2016
42
Application of diffusional kurtosis imaging to detect occult brain damage in multiple sclerosis and neuromyelitis optica. ( 27602543 )
2016
43
Imbalance in multiple sclerosis and neuromyelitis optica: association with deep sensation disturbance. ( 27576580 )
2016
44
Neuromyelitis optica and tactile and visual hallucinations in an elderly patient. ( 27625153 )
2016
45
Transverse Myelitis and Neuromyelitis Optica Spectrum Disorders. ( 27616312 )
2016
46
Low serum uric acid levels in patients with multiple sclerosis and neuromyelitis optica: An updated meta-analysis. ( 27645338 )
2016
47
Higher frequency of brain abnormalities in neuromyelitis optica spectrum disorder patients without primary SjAPgren's syndrome. ( 27904495 )
2016
48
Multifrequency magnetic resonance elastography of the brain reveals tissue degeneration in neuromyelitis optica spectrum disorder. ( 27572811 )
2016
49
Neuromyelitis optica study model based on chronic infusion of autoantibodies in rat cerebrospinal fluid. ( 27193196 )
2016
50
Three cases of neuromyelitis optica spectrum disorder. ( 27293805 )
2016

Variations for Neuromyelitis Optica

Expression for Neuromyelitis Optica

Search GEO for disease gene expression data for Neuromyelitis Optica.

Pathways for Neuromyelitis Optica

GO Terms for Neuromyelitis Optica

Cellular components related to Neuromyelitis Optica according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 integral component of lumenal side of endoplasmic reticulum membrane GO:0071556 9.16 HLA-DPB1 HLA-DRB1
2 MHC class II protein complex GO:0042613 8.96 HLA-DPB1 HLA-DRB1
3 external side of plasma membrane GO:0009897 8.92 AQP4 HLA-DRB1 IL17A IL6

Biological processes related to Neuromyelitis Optica according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 renal water homeostasis GO:0003091 9.46 AQP1 AQP4
2 positive regulation of interleukin-6 secretion GO:2000778 9.43 IL17A MBP
3 T cell costimulation GO:0031295 9.43 HLA-DPB1 HLA-DRB1 TNFSF13B
4 water transport GO:0006833 9.4 AQP1 AQP4
5 antigen processing and presentation of peptide or polysaccharide antigen via MHC class II GO:0002504 9.37 HLA-DPB1 HLA-DRB1
6 positive regulation of T cell proliferation GO:0042102 9.33 HLA-DPB1 IL6 TNFSF13B
7 multicellular organismal water homeostasis GO:0050891 9.32 AQP1 AQP4
8 immune response GO:0006955 9.1 HLA-DPB1 HLA-DRB1 IL17A IL6 MBP TNFSF13B
9 positive regulation of transmission of nerve impulse GO:0051971 8.96 HCRT IL6

Molecular functions related to Neuromyelitis Optica according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 peptide antigen binding GO:0042605 9.16 HLA-DPB1 HLA-DRB1
2 water channel activity GO:0015250 8.96 AQP1 AQP4
3 water transmembrane transporter activity GO:0005372 8.62 AQP1 AQP4

Sources for Neuromyelitis Optica

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 MedGen
42 MeSH
43 MESH via Orphanet
44 MGI
46 NCI
47 NCIt
48 NDF-RT
51 NINDS
52 Novoseek
54 OMIM
55 OMIM via Orphanet
59 PubMed
60 QIAGEN
65 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....